ABSTRACT: Although certainly not the first line treatment for plantar fibromas, surgical resection is a treatment option for some patients with have failed exhaustive non-surgical treatment. The use of topical Mitomycin C has been recently shown to reduce the recurrence rate of other fibrous lesions. The purpose of this study was to determine the impact of topical application of Mitomycin C on recurrence rate of plantar fibromas. A retrospective analysis was done from a prospectively gathered database with a total 50 consecutive patients over a 16-month study period. The control group (n ¼ 29) consisted of patients who underwent only surgical resection, while the study group (n ¼ 21) consisted of patients who underwent surgical resection with adjuvant therapy using Mitomycin C. The primary endpoint was local recurrence after the procedure. Secondary end points included complications and toxicity associated with this medication. No patients were lost to follow up. Of the 29 patients in the control group, there were 17 patients (17/29, 58.6%) had recurrence of the plantar fibroma at a mean follow-up of 9.1 months. In contrast, in the experimental study group, all patients were free from local recurrence. No complications or side effects were associated with Mitomycin C use. The results demonstrate that the topical application of Mitomycin C to the tumor bed after surgical resection of plantar fibromas reduced the recurrence rate. ß
Plantar fibromas are slow growing, benign but locally aggressive soft tissue tumors of the foot. They begin as a subcutaneous thickening of the medial and central bands of the plantar fascia. 1 Most plantar fibromas are commonly found bilaterally, with an incidence ranging from 10 to 50%, and most commonly affecting males between the ages of 20-40. 1 Although most plantar fibromas do not exceed 2 cm in width and 3 cm in length, some fibromas as large as 10.5 cm have been reported. 1 In addition, plantar fibromas occur with a higher frequency in patients with other fibrotic soft tissue diseases. In patients with Dupytren's contractures and Peyronie's disease, the incidence can be as high as 65% and 4%, respectively. [2] [3] [4] Non-surgical treatment is effective for the majority of patients with plantar fibromas. Asymptomatic plantar fibromas are generally observed, but physical therapy can be initiated when patients experience symptoms of pain or discomfort upon weight bearing. This regimen is similar to that of plantar fasciitis and primarily involves stretching. Conservative management can also consist of custom molded orthotics which disperses the pressure at the mass with weight bearing and relieves tension off of the plantar fascia. 1 In a case study by Knobloch and Vogt, 5 extracorporeal shockwave therapy was shown to reduce pain associated with plantar fibromas in Lederhose patients.
When these measures fail, surgical excision may be considered. However, the average rate of recurrence after excision has been reported to be approximately 60%. 6 Several factors have been shown to be associated with an increased rate of recurrence, such as family history, multiple nodules, and bilateral lesions. 7 A recent study suggested that phenobarbital may contribute to recurrence of plantar fibromas in epileptic patients, suggesting that other extrinsic factors may play a role as well. 8 A recent study evaluated 38 pediatric patients who underwent excision of both palmar and plantar fibromas with 14-year average follow up. Here a recurrence rate of 84.2% was reported. 9 Similarly, a study by Durr et al. 10 evaluated 11 patients who underwent a total of 24 procedures that included marginal excision, wide excision or subtotal fasciectomy of fibromas. Their results showed that two patients treated with fasciectomies did not recur, yet seven of nine wide excisions, three of six revised fasciectomies, and six of seven local resections recurred.
Several medications have been used to treat plantar fibromas. Topical transdermal verapamil gel and corticosteroid injection into the lesion have been shown to reduce the size of the fibromas, however no effect on the recurrence rate was found. 11 In another recent study, forty patients with plantar fibromas were administered 400 mg of oral Imatinib without surgical intervention over a period of 2 years, in which there was a 45% recurrence rate of the tumors. 12 Mitomycin C is an antitumor antibiotic isolated from Streptomyces caespitosus. Lee et al. 13, 14 has shown that mitomycin C has an anti-fibroblastic effect. The exact mechanism of action is not fully understood, but inhibition of fibroblast proliferation is involved. The use of Mitomycin C has been primarily used to treat bladder cancer. 15 The topical use of Mitomycin C has safely been used to decrease the amount of keloid scar formation and recurrent conjunctival corneal squamous cell carcinoma. 14, 16 Topical application of Mitomycin C has only a rare side effect of dermatitis, which is mild and self limiting. 17, 18 In contrast, the side effects of intravenous (IV) administration of Mitomycin C are serious and potentially life threatening, 19 however topical administration has not been associated with these side effects. Recent studies have demonstrated a decrease in recurrence rate of pterygiums, benign fibrovascular growths of the conjunctiva, with the topical addition of Mitomycin C. 20 This drug has also been shown to prevent scar tissue formation after glaucoma filtration surgery, canine subglottic surgery, pediatric choanal atresia repair, rabbit maxillary antrostomy surgery, and tracheal stenosis repair. [21] [22] [23] [24] [25] While the biological nature of plantar fibromas is not well understood, it is generally accepted that fibroblast proliferation is the main problem.
14 This drug has been used successfully in several fibrosing conditions. No systemic adverse effects have been reported with the topical application of Mitomycin C. For these reasons, we hypothesized that the utilization of topical Mitomycin C as an adjuvant therapy to surgical resection of plantar fibromas would decrease the rate of recurrence.
The purpose of this study was to determine the impact of topical application of Mitomycin C on recurrence rate of plantar fibromas. We hypothesized that topical application to the tumor bed after surgical resection could reduce recurrence rate. Secondary outcome measures included wound complication rate, and adverse systemic effects associated with application of Mitomycin C and risk factors associated with recurrence.
PATIENTS/MATERIALS AND METHODS
The original therapeutic intervention was performed by a surgical podiatric practice and data collected. Only deidentified data was transmitted to the current authors for analysis. IRB for reviewing patient information was obtained prior to study. This study details the retrospective analysis on the de-identified data provided to the authors for analysis, and does not represent the original therapeutic intervention study. All patients with a diagnosis of plantar fibroma requiring surgery during a 16-month period were included, totaling 50 patients. The control group (n ¼ 29) consisted of consecutive patients that underwent only surgical resection of their mass. The study group (n ¼ 21) consisted of consecutive patients who underwent surgical resection followed by the topical application of Mitomycin C to the tumor bed after resection as adjuvant therapy. All patients were surgically treated by a single surgeon between March 2014 and July 2015, and had a minimum follow-up of 6 months. There was no randomization; patients were given adequate information for an informed consent, and could choose to have the drug or not. In some instances, the drug was not available to the patient because of lack of insurance coverage of the offlabel usage. The patients who did not receive the drug during the study period formed the control group, while the patients receiving the drug during the same period formed the study group. All patients were informed that clinical, histological, and radiographic data could be used for scientific purposes.
Inclusions/Exclusion
All patients presenting with a foot mass that was clinically felt to be a plantar fibroma who failed exhaustive nonsurgical management were included in this study. Diagnostic ultrasound was used to confirm the diagnosis. Patients initially underwent conservative therapy including information on stretching, physical therapy, therapeutic ultrasound treatment 26, 27 and corticosteroid injection, for a minimum 6-month period. Failed conservative treatment, persistently symptomatic lesions, and patient preference were used as inclusion criteria for surgery. Patients who had been previously treated with surgical resection or ablation were excluded. Other exclusion criteria for this study included previous treatment for the same lesion else-where, patients unable to undergo surgery due to existing comorbidities, patients with known allergies to Mitomycin C, and patients presenting with recurrent plantar fibromas. A prestudy questionnaire was administered to confirm that all participants met the inclusion criteria.
Patient Characteristics
Fifty patients with a diagnosis of plantar fibroma underwent surgical excision. Approximately 125 patients were successfully treated conservatively for plantar fibromas by the practice during this same period. Histology was confirmed on excision of specimen. All 50 patients were available at 6 months follow up. Thirty-Eight patients and 15 patients were available for 12 and 24 months' follow-up, respectively. Patient demographics including age, gender, date of birth, date of surgery, follow-up time period, and comorbidities was documented and recorded. The mean and range of values were noted for all variables.
Tumor Characteristics
Tumor characteristics including including size and volume were documented. The mean and range of values were noted for all variables. Measurements of tumor size were based on biopsy samples.
Surgical Technique Protocol
If a patient fails non-surgical management, surgical resection is performed. All masses were excised with marginal margins by the same surgeon. The surgical procedure involves an incision on the plantar aspect of the foot. The central and medial bands of the plantar fascia are reflected and any diseased portions are removed. For the experimental group, once the tumor is resected, topical Mitomycin C [6cc, 0.4 mg/ml] (Mutamycin; Bristol Laboratories, Princeton, NJ), is applied to the tumor bed using a cotton applicator for 5 min. In an attempt to prevent dilution, meticulous hemostasis is achieved prior to its application. After 5-min, the wound is again irrigated with 100 ml of isotonic sodium chloride solution. Afterwards, the incision is closed in standard layers. Postoperatively, the patient is maintained non-weight-bearing in a surgical shoe and crutches until the wound is healed.
Normal post-operative care including rest, ice, elevation, and maintaining a clean surgical site is ordered. The sutures are removed between 2 and 3 weeks after the surgery. The patient is then instructed to begin WBAT in a controlled ankle motion (CAM) walker and gradually initiate nonrestricted weight bearing. Long-term, custom-molded orthoses or insoles are recommended to the patient for arch support during the recovery period.
Patients are advised to follow-up in 6 month intervals. Any wound problems are noted at each follow up. Local recurrence after the procedure is determined clinically based on history and physical examination during follow-up visits. Diagnostic ultrasound is used for the determination of recurrence in all patients. If diagnostic ultrasound can not provide confirmation, then magnetic resonance imaging (MRI) is used.
Statistical Analysis
Logistic regression analysis was conducted by a statistician to determine if any clinical risk factors (age, gender, tumor size) were associated with increased risk of recurrence of plantar fibromas after surgical resection. Analysis of the data was performed with IBM SPSS Statistics for Windows (version 22; IBM). If applicable, differences in means were tested with the Student t-test, and a p-value of <0.05 was considered significant.
RESULTS

Patient Characteristics
A total of 50 patients were included in the study. No patients were lost to initial follow-up ( Table 1) . The mean age for all the patients was 52.9 years (range: 21-83 years), with an overall male-tofemale ratio of 0.8:1. The overall average follow-up time for all the patients was 14.3 months (range 6.2-24 months). Patients included in this study had comorbidities that included hypertension
, chronic obstructive pulmonary disease (n ¼ 3), and chronic kidney disease (n ¼ 2). Thirteen patients did not have any comorbidities. There was no statistical difference (p > 0.05) between the two groups regarding patient age, gender, or past medical history and therefore the two groups were statistically homogenous and comparable. ).
Primary Outcome
Of the 29 patients in the control group, 17 (58.6%) patients had recurrence at a mean follow up of 13.2 months (range: 6-24 months). Of these 17 patients, four had recurrence by 6 months, 11 patients by 12 months, and all 17 by 24 months. The average time of disease recurrence for these patients was 9.1 months. In contrast, in the experimental study group with Mitomycin C use, all patients were free from local recurrence at a mean follow-up of 15.9 months (range: 6-24 months) (Fig. 1A significant difference in the rate of recurrence between the two groups was found (p < 0.0001) ( Table 2) .
In order to determine if there was a significant difference in the demographics between patients who had local recurrence of disease and those who remained disease free, a chi-squared analysis was conducted. It was found that there was no statistical difference between patients in these two groups in terms of gender, age, and tumor size (p > 0.05).
Using a Cox proportional hazards regression, the only variables that were shown to be statistically significant and associated with increased rate of recurrence were female gender and increased tumor size. When comparing males and females, the hazard ratio of females developing recurrence compared to males was 4.15 (p ¼ 0.01). Similarly, when comparing tumor sizes, larger tumors (>1 cm 3 ) had a hazard ratio of 1.21 compared to smaller sized tumors (p ¼ 0.001). In contrast, no significant difference in the hazard ratio with respect to age of patient at diagnosis was found (p ¼ 0.22). Kaplan-Meier plots of gender versus time to recurrence and tumor size versus time to recurrence are shown below (Figs. 2 and 3 ).
Complications
In our Mitomycin cohort, we had a 14.3% rate (3/21 patients) of wound infection, treated with antibiotics alone. In the control group, we had a 13.8 % rate (4/29 patients) of wound infection, treated with antibiotics alone. No significant difference in the rates of wound complications was found (p ¼ 0.91) ( Table 2 ). All skin infections in both groups occurred in patients with non insulin dependent diabetes mellitus. In addition, in the control group, of four patients that had skin infection, three were chronic smokers and one suffered from peripheral vascular disease. Similarly, in the Mitomycin group, of the three patients, two were also chronic smokers and one patient had peripheral vascular disease. Infections were treated with antibiotics, wound debridement, and dressing changes as necessary. No patient in either group required a return to the operating room.
DISCUSSION
The findings of this study demonstrated a zero recurrence rate of plantar fibromas with the topical use of Mitomycin C as an adjuvant to surgical resection when compared to surgical resection alone. Our study also demonstrated that the rate of wound infection in the Mitomycin C group was not statistically different from that in the control group and is consistent with other studies regarding this topic. In addition, although this condition most commonly occurs in men, there were more women (54%) in our study. It is unlikely that this would have any effect on the recurrence rate reported in this study. The results of the regression analysis demonstrated that females and larger sized tumors were associated with increased risk of recurrence.
All patients in the experimental group (Mitomycin C group) were free from local recurrence at a mean follow-up of 15.9 months (range: 6-24 months). In comparison, the control group had a 58.6% recurrence rate at 13.24 months. Table 3 shows a summary of studies on excision methods of plantar fibromas in the current literature with their respective rates of recurrence. 6, 7, 9, 10, 28, 29 In a study conducted by van der Veer et al., 6 27 patients who had undergone surgical removal of plantar fibromas were evaluated. Their results indicated an overall 60% recurrence rate of the mass upon follow up; of these total plantar fasciectomy had a recurrence at 25%, while marginal resection of the masses resulted in recurrence 100% of the time. 6 Other surgical options include subtotal fasciectomy. Aluisio et al. 7 performed a study comparing the outcomes of 30 patients who had undergone local excision, wide excision, or subtotal fasciectomies between 1979 and 1993. Four of 17 patients (23.5%) who had a subtotal fasciectomy experienced a recurrence. They concluded that although not a definite cure, the subtotal approach is the most effective treatment for plantar fibromas. Similarly, a study by Durr et al. evaluated 11 patients who underwent a total of 24 procedures that included marginal excision, wide excision or subtotal fasciectomy. Their results were that two initial fasciectomies did not recur, yet seven of nine wide excisions, three of six revised fasciectomies, and six of seven marginal resections recurred. 10 These results demonstrate that even with aggressive surgical excision, the recurrence rate has still been higher than would be considered acceptable. The results of this study indicate that Mitomycin is preventing the proliferation and reformation of these tumors by blocking fibroblastic activity as would be suspected given its known biologic activity. Additionally, the patients in this series did not need to undergo more radical surgery than a simple marginal excision, which lowers surgical risk. It is possible that Mitomycin C simply delays recurrence. Further follow up is necessary to determine intermediate and long-term outcomes.
Recurrences were determined both clinically and with the use of diagnostic ultrasound for all patients. This helped minimize the chance that these results are due to asymptomatic or smaller recurrences that are less easily clinically determined occurring in patients treated with topical Mitomycin C. MRI, a much more sensitive imaging modality, was not used primarily for the detection of plantar fibromas or recurrence. However, follow up MRI is not routinely used to detect recurrence in this condition in clinical practice, and asymptomatic recurrences are generally clinically insignificant, and therefore we did not feel routine MRI scanning would reflect standard clinical practices.
Although fasciectomy seems to be the most effective surgical treatment, it is associated with a higher complication risk than wide excision. Baxter's nerve (first branch of the lateral plantar nerve), is at risk for injury during a total fasciectomy. 30 Additionally, in a case study by Pontious et al., 31 a patient developed hammertoes due to loss of digital stabilization after removal of a portion of the plantar aponeurosis. Loss of the tension bands in the plantar aspect of the foot can lead to a loss of arch support as a postoperative complication. 31 This indicates that an adjuvant treatment that allows a lesser surgical procedure could potentially help decrease the risk of surgical complication. In only a few studies, functional outcome after surgical resection of plantar fibromas were reported satisfactory in 60-80% of cases. 7, 29, 32, 33 Nonsurgical treatment regimens have included laser excision or vaporization, corticosteroid injection, calcium channel blocker injection, cryotherapy, pressure therapy, radiation therapy, and combinations of any of the listed modalities.
12,34-38 Most, if not all, of these interventions have failed to significantly reduce recurrence risk (Table 4) . Several authors have demonstrated that injecting collagenase from Clostridium Histolytica produced an improvement in release of contractures of the metacarpophalangeal and proximal phalangeal joints. 39 We also looked at the rate of wound complications after the administration of Mitomycin C to ensure the agent was in fact safe and did not contribute any toxicity to the wound or delay wound healing. The rate of wound infection in the Mitomycin C group was not statistically different from that in the control group and is consistent with other studies regarding this topic. There is limited information on the rate of wound healing and infection following surgical excisions in the literature. Plantar wounds after removal of plantar fibromas ranges from 3% to 30%. 34, 35 In one study by Sammarco et al., 32 the rate of delayed healing was 52%. This study suggests that Mitomycin C does not impart additional wound toxicity, nor does it make it more or less likely that a wound infection would need operative management. Although this condition most commonly occurs in men, there were 27 women (54%) in our study.
1 A larger proportion of female patients was found in the experimental group (14/21, 67.7%). In contrast, the male to female ratio was more preserved in the control group (14/29, 48.3%), which is closer to the expected ratio. Age range was broad for both study groups, but reflective of the incidence of this disorder in the population. The rates of recurrence are higher in females was an unexpected finding. The current literature shows that rates of recurrence was seen higher in males. 33 In fact, Ledderhose Disease, a disease with severe plantar fibromas affects men approximately 10 times more often than women. 40 It is unlikely that the increased proportion of females would have any effect on the recurrence rate reported in this study. In addition, the results of the regression analysis, it was shown that females and patients with larger tumors were associated with increased risk of recurrence. Further study is needed to confirm these data as these findings may be useful to help guide prognosis and management. If a female patient presents with a large tumor, a discussion may be warranted about an increased risk of recurrence compared to other patient populations. No significant association with age of diagnosis and recurrence was found, possibly due to an underpowered study. The results demonstrated that there might be a trend for older diagnosed patients to have a decreased rate of recurrence. One possible explanation is that with increased age, patients develop less aggressive disease and thus have a decreased rate of recurrence.
To our knowledge, the present study is the first to examine the efficacy of Mitomycin C in preventing the recurrence of plantar fibromas following surgical resection. In our case-controlled study with a minimum follow-up of 6 months, we demonstrated that its topical application is a safe and effective adjuvant therapy in the short term. There are significant limitations to this study. These limitations include its retrospective design, no real randomization process introducing the possibility of significant bias, and the lack of functional outcomes. Additionally, the small sample size and short term follow-up time period might not identify fibroma recurrences that occur with longer follow-up or identify potential longer-term toxicity of Mitomycin C treatment. However, in spite of these limitations, we feel that the data presented here are encouraging and may suggest an effective method of decreasing recurrence rate of surgically excised plantar fibromas. Further study of this novel technique is warranted.
In conclusion, although the vast majority of plantar fibroma patients can be effectively treated with non-surgical methods, this technique may offer a reasonable alternative for those with fibromas that remain persistently symptomatic despite non-surgical treatment. These data suggest a possible role for Mitomycin C as an adjunct treatment for marginal excision of plantar fibromas.
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